Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Cross Below 200 Day Moving Average – Should You Sell?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $11.09 and traded as low as $11.08. Ono Pharmaceutical shares last traded at $11.08, with a volume of 540 shares changing hands.

Ono Pharmaceutical Trading Down 9.2%

The company’s fifty day simple moving average is $11.35 and its two-hundred day simple moving average is $11.09. The company has a quick ratio of 2.44, a current ratio of 2.99 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $5.20 billion, a price-to-earnings ratio of 17.87 and a beta of 0.17.

Ono Pharmaceutical (OTCMKTS:OPHLF) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Ono Pharmaceutical had a net margin of 8.75% and a return on equity of 5.47%. The company had revenue of $876.10 million during the quarter, compared to analyst estimates of $790.87 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.